(Q42245782)

English

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

scientific article published on 17 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

6

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

4

object named as

Stanislas Pol

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

12

object named as

Andrzej Horban

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Zobair Younossi

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Francesco Negro

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Lawrence Serfaty

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Moises Diago

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Pietro Andreone

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Eric J Lawitz

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Stuart Roberts

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Roberto Focaccia

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Graham R Foster

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Isabelle Lonjon-Domanec

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Bruce Coate

14

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ralph DeMasi

15

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Gaston Picchio

16

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

James Witek

17

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

17 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1897-1906

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Meta-analysis: insulin resistance and sustained virological response in hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Signalling links in the liver: knitting SOCS with fat and inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26437

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42245782&oldid=1939797798"